Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07594093 · ClinicalTrials.gov registry record · Phase 1
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT07594093 is a Phase 1 study that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 90 participants.
The verdict
NCT07594093, a Phase 1 study, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity. The study is looking at: * What side effects REGN20934 might cause * How much REGN20934 is in the blood at different times * If the body makes antibodies to REGN20934
Interventions
- DRUG Placebo
- DRUG REGN20934
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-06-29 |
| Est. Completion | 2027-02-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07594093
The ClinicalTrials.gov registry entry for NCT07594093 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07594093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07594093 about?
NCT07594093 is a clinical study titled "Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity". This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity. The study is looking at: * What side effects REGN20934 might cause * How much REGN20934 is in the blood ...
What is the current status of trial NCT07594093?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2026-06-29. Estimated completion is 2027-02-22.
What interventions are being tested in trial NCT07594093?
The interventions under investigation include: Placebo (DRUG), REGN20934 (DRUG).
Who is sponsoring clinical trial NCT07594093?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.